Canary Oncoceutics

Canary Oncoceutics is a new company that uses cellular technology to develop in vitro precision oncology tests. The company is developing a precise tumor testing platform that will complement existing cancer genomic testing. The company tests patients' tumors in a laboratory setting, allowing doctors to refine a list of recommendations generated by genomic testing into the most effective drugs or drug combinations for specific patients. This revolutionary precision oncology functional approach is enabled by technology licensed to Canary Oncoceutics from Cornell University. The technology creates a fully vascularized patient tumor in vitro using endothelial cells and tumors obtained from patients through biopsy. No artificial scaffolds or devices are required, allowing patient blood to perfuse into patient-derived tumor-like bodies. The system is being designed to test various drugs for tumor-killing effects, and the company will continue to study the effects of drugs on cancer stem cells.